Shares of Rubius Therapeutics Inc (NASDAQ:RUBY) have received an average rating of “Buy” from the seven ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $25.00.
A number of brokerages recently issued reports on RUBY. Robert W. Baird began coverage on Rubius Therapeutics in a research report on Monday. They issued an “underperform” rating and a $4.00 target price on the stock. JPMorgan Chase & Co. cut their target price on Rubius Therapeutics from $27.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, August 29th. Zacks Investment Research raised Rubius Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 24th. Guggenheim began coverage on shares of Rubius Therapeutics in a research note on Thursday, May 30th. They set a “buy” rating and a $25.00 price target for the company. Finally, HC Wainwright started coverage on shares of Rubius Therapeutics in a report on Wednesday, June 26th. They issued a “buy” rating and a $40.00 price objective on the stock.
In other news, Director Robert Langer sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $14.94, for a total transaction of $112,050.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Christopher L. Carpenter sold 47,757 shares of the stock in a transaction that occurred on Wednesday, June 19th. The shares were sold at an average price of $14.02, for a total value of $669,553.14. The disclosure for this sale can be found here. Insiders own 58.40% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC increased its holdings in Rubius Therapeutics by 0.4% during the first quarter. Jennison Associates LLC now owns 479,398 shares of the company’s stock worth $8,677,000 after buying an additional 1,802 shares during the last quarter. Bank of Montreal Can bought a new stake in Rubius Therapeutics during the second quarter worth $46,000. Tower Research Capital LLC TRC bought a new stake in Rubius Therapeutics during the second quarter worth $67,000. Metropolitan Life Insurance Co NY lifted its stake in Rubius Therapeutics by 65.0% in the first quarter. Metropolitan Life Insurance Co NY now owns 11,867 shares of the company’s stock valued at $214,000 after acquiring an additional 4,676 shares during the last quarter. Finally, MetLife Investment Advisors LLC lifted its stake in Rubius Therapeutics by 52.2% in the first quarter. MetLife Investment Advisors LLC now owns 16,410 shares of the company’s stock valued at $297,000 after acquiring an additional 5,629 shares during the last quarter. 97.74% of the stock is owned by institutional investors and hedge funds.
Shares of RUBY traded up $1.04 during midday trading on Friday, hitting $9.79. The stock had a trading volume of 314,322 shares, compared to its average volume of 269,685. The firm has a market cap of $755.89 million, a price-to-earnings ratio of -4.31 and a beta of 2.25. The company has a 50 day simple moving average of $10.96 and a two-hundred day simple moving average of $14.76. Rubius Therapeutics has a twelve month low of $8.54 and a twelve month high of $24.49. The company has a debt-to-equity ratio of 0.21, a current ratio of 17.27 and a quick ratio of 17.27.
Rubius Therapeutics (NASDAQ:RUBY) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.04). During the same period in the prior year, the business earned ($3.33) earnings per share. Analysts forecast that Rubius Therapeutics will post -2.02 EPS for the current fiscal year.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
Featured Article: Certificate of Deposit (CD) For Risk Adverse Investors?
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.